Temporary right ventricular mechanical circulatory support for the management of right ventricular failure in critically ill patients
| Autor: | Nadia Aissaoui, Michael Schoenbrodt, Jochen Börgermann, Michiel Morshuis, Jan Gummert, L Kizner, Kavous Hakim Meibodi |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine medicine.medical_specialty Time Factors Critical Illness Ventricular Dysfunction Right medicine.medical_treatment Internal medicine medicine Humans Prospective Studies Heart Failure Mechanical ventilation Framingham Risk Score Critically ill business.industry High mortality Middle Aged equipment and supplies Right Ventricular Assist Device Ventricular assist device Circulatory system Cardiology Right ventricular failure Female Surgery Heart-Assist Devices Cardiology and Cardiovascular Medicine business |
| Zdroj: | The Journal of Thoracic and Cardiovascular Surgery. 146:186-191 |
| ISSN: | 0022-5223 |
| DOI: | 10.1016/j.jtcvs.2013.01.044 |
| Popis: | BackgroundManagement of right ventricular (RV) failure after left ventricular assist device (LVAD) implantation is not evidence based. Temporary circulatory assistance has recently been reported to be of value for managing postoperative RV failure after LVAD implantation, but only in small series of patients or isolated case reports. We report here our experience with the use of temporary right ventricular assist devices (RVADs) in LVAD recipients.MethodsForty-five of the 488 (9%) patients undergoing LVAD implantation between 2001 and 2011 at the Clinic for Thoracic and Cardiovascular Surgery in Bad Oeynhausen had RV failure requiring temporary RVAD. We analyzed preoperative data, complications, mortality at 6 months, and risk factors of death.ResultsThe LVAD patients receiving temporary RVAD were younger than the 443 recipients of LVAD alone. They were more likely to have mechanical ventilation and haemofiltration and their Michigan right ventricular risk score was higher. The LVAD patients with temporary RVAD had a higher mortality at 6 months: 53%, versus 25% for patients receiving LVAD only (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|